obesity drug news today glp-1 october 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 obesity drug news today glp-1

In 2025, Hims & Hers aired a provocative national ad promoting compounded GLP-1 medications as a lower-cost, accessible alternative to Big Pharmas pricing

Patients with severe gastrointestinal disease (gastroparesis, inflammatory bowel disease) may have difficulty tolerating these medications

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al

Announcing the preclinical milestone, Nimbus signaled that it was looking beyond cardiometabolic disorders, into weight loss and management: I look forward to continuing to apply Nimbus discovery engine to address targets across metabolic, cardiovascular, and obesity-related diseases, Peter J

Generally, these medications all work by curbing appetite, but they do so slightly differently

This long history of use provides strong evidence of their safety when prescribed and monitored by healthcare professionals